In patients with OC, BRCA-mutated patients had a significant PFS benefit compared with BRCAwt cancer (HR: 0.65; 95% CI, 0.44 to 0.98, p = 0.032) with PARP inhibitors; with no significant difference in somatic and germline mutations carriers [19]. The gene discussed is PARP1; the disease is cancer.